InvestorsHub Logo
Followers 158
Posts 10559
Boards Moderated 2
Alias Born 10/14/2001

Re: sam1933 post# 78566

Sunday, 06/22/2008 10:47:23 AM

Sunday, June 22, 2008 10:47:23 AM

Post# of 82595
…Hermann Lübbert. “Improving the patient selection by DNAPrint's unique technology will render Biofrontera’s clinical trials less costly and expedite the development of our drugs. We consider the ability to predict the individual patient's response to our drugs an extremely valuable addition to our effort in serving the patients' needs. Rapid success in drug development will move Biofrontera towards its goal of an initial public offering.”

http://www.bio-pro.de/en/region/rhein/meldungen/00864/index.html

April 02, 2008
Rapid progress in phase III studies for BF-200 ALA in the treatment of actinic keratosis
http://www.biofrontera.com/index.php?id=8